Home » Stocks » Homology Medicines

Homology Medicines, Inc. (FIXX)

Stock Price: $15.34 USD 0.09 (0.59%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 693.57M
Revenue (ttm) 1.98M
Net Income (ttm) -115.40M
Shares Out 45.21M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $15.34
Previous Close $15.25
Change ($) 0.09
Change (%) 0.59%
Day's Open 15.46
Day's Range 15.10 - 15.50
Day's Volume 294,561
52-Week Range 11.05 - 24.00

More Stats

Market Cap 693.57M
Enterprise Value 474.52M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.21M
Float 23.36M
EPS (basic) -2.61
EPS (diluted) -2.62
FCF / Share -2.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.68M
Short Ratio 6.91
Short % of Float 7.95%
Beta -0.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 349.58
PB Ratio 3.11
Revenue 1.98M
Operating Income -121.31M
Net Income -115.40M
Free Cash Flow -112.73M
Net Cash 219.05M
Net Cash / Share 4.84
Gross Margin -4,421.98%
Operating Margin -6,114.52%
Profit Margin -5,816.30%
FCF Margin -5,682.11%
ROA -29.06%
ROE -57.58%
ROIC -56.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$32.22*
(110.04% upside)
Low
24.0
Current: 15.34
High
37.0
Target: 32.22
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue1.675.32--
Revenue Growth-68.7%---
Gross Profit1.675.32--
Operating Income-110-59.93-29.66-10.00
Net Income-104-55.58-29.99-8.05
Shares Outstanding42.1228.552.481.90
Earnings Per Share-2.47-1.95-12.10-4.23
Operating Cash Flow-91.36-42.566.48-8.48
Capital Expenditures-21.83-24.94-1.96-1.99
Free Cash Flow-113-67.504.52-10.47
Cash & Equivalents26421713111.67
Net Cash / Debt26421713111.67
Assets31125913814.22
Liabilities52.0662.7439.226.72
Book Value259196-39.45-9.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Homology Medicines, Inc.
Country United States
Employees 195
CEO Arthur O. Tzianabos

Stock Information

Ticker Symbol FIXX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FIXX

Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.